DelveInsight's report on Acute Bacterial Skin and Skin-Structure Infections (ABSSSI) forecasts significant market growth by 2034, driven by rising prevalence and awareness. Key players include Glenmark Pharma and AbbVie, with therapies like Zevtera and Dalbavancin leading the charge. The report highlights a higher incidence in men and notes nearly 870,000 hospital admissions in the U.S. due to ABSSSI in 2004.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.